Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade
Source abstract
Abstract
ABSTRACT Lactate reshapes the tumor microenvironment (TME) through complex communication between cancer and stromal cells. However, it remains undefined whether lactate mediates the interaction between pancreatic cancer (PC) cells and pancreatic stellate cells (PSCs), a significant TME component driving tumorigenesis. This study elucidates the metabolic crosstalk between PC cells and PSCs underlying lactate‐driven tumor progression. Our findings demonstrate that PC cells serve as the primary lactate source in the TME, where lactate induces PSC activation through an autophagy‐dependent mechanism mediated by protein lactylation. This activation cascade subsequently upregulates programmed cell death‐1 (PD‐1) expression in CD8 + T cells, promoting immune evasion. Notably, AZD3965, a specific MCT1 inhibitor, sensitizes orthotopic PC to PD‐1 blockade, effectively inhibiting tumor development. Mechanistically, MCT1‐mediated lactate influx activates PSCs by inducing lactylation of lysine residues K356 and K781 on Vps34, a key autophagy regulator. Moreover, activated PSCs secrete CXCL9/CXCL10, which upregulates PD‐1 expression in CD8 + T cells via the CXCR3/STAT3 pathway. This study establishes lactate as a crucial TME signaling molecule orchestrating PSC activation and an immunosuppressive microenvironment, providing compelling evidence for combining MCT1 inhibition with immune checkpoint blockade for pancreatic cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Cancer Immunotherapy and Biomarkers · Autophagy in Disease and Therapy
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Emergency Surgery Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
Funding
National Natural Science Foundation of China
References (49)
Show source-provided references
1. 10.1158/1078‐0432.CCR‐14‐260710.1158/1078‐0432.CCR‐14‐2607 ↗
2. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial10.1001/jamaoncol.2019.1588 ↗
3. 10.1056/NEJMoa120069410.1056/NEJMoa1200694 ↗
4. 10.1016/j.cell.2021.07.02010.1016/j.cell.2021.07.020 ↗
5. 10.1016/j.ccell.2021.02.00710.1016/j.ccell.2021.02.007 ↗
6. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment10.1053/j.gastro.2022.02.024 ↗
7. 10.1016/j.semcancer.2022.08.00910.1016/j.semcancer.2022.08.009 ↗
8. 10.1016/j.cell.2012.01.05810.1016/j.cell.2012.01.058 ↗
9. 10.1016/j.celrep.2022.11079210.1016/j.celrep.2022.110792 ↗
10. 10.1007/s00262‐024‐03898‐w10.1007/s00262‐024‐03898‐w ↗
11. 10.1016/j.ccell.2022.01.00110.1016/j.ccell.2022.01.001 ↗
12. 10.1186/s12943‐024‐02008‐910.1186/s12943‐024‐02008‐9 ↗
13. 10.1016/j.canlet.2023.21628510.1016/j.canlet.2023.216285 ↗
14. Elevated Protein Lactylation Promotes Immunosuppressive Microenvironment and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma10.1172/JCI187024 ↗
15. 10.1038/s41422‐019‐0195‐y10.1038/s41422‐019‐0195‐y ↗
16. 10.1136/gutjnl‐2011‐30122010.1136/gutjnl‐2011‐301220 ↗
17. 10.1073/pnas.161403511410.1073/pnas.1614035114 ↗
18. Why Warburg Works: Lactate Controls Immune Evasion Through GPR8110.1016/j.cmet.2020.03.001 ↗
19. 10.1124/pr.119.01876210.1124/pr.119.018762 ↗
20. Pancreatic Acinar Cells‐Derived Sphingosine‐1‐Phosphate Contributes to Fibrosis of Chronic Pancreatitis via Inducing Autophagy and Activation of Pancreatic Stellate Cells10.1053/j.gastro.2023.08.029 ↗
21. 10.1053/j.gastro.2017.01.01010.1053/j.gastro.2017.01.010 ↗
22. 10.4161/auto.2028410.4161/auto.20284 ↗
23. 10.1073/pnas.12114589810.1073/pnas.121145898 ↗
24. 10.1126/sciadv.adg499310.1126/sciadv.adg4993 ↗
25. 10.1038/s41577‐021‐00540‐z10.1038/s41577‐021‐00540‐z ↗
26. 10.1038/s41594‐023‐01175‐510.1038/s41594‐023‐01175‐5 ↗
27. 10.1172/JCI7195110.1172/JCI71951 ↗
28. 10.4049/jimmunol.130275010.4049/jimmunol.1302750 ↗
29. 10.1016/j.xgen.2024.10065910.1016/j.xgen.2024.100659 ↗
30. 10.1016/0092‐8674(94)90361‐110.1016/0092‐8674(94)90361‐1 ↗
31. 10.3390/antiox1210181810.3390/antiox12101818 ↗
32. 10.3390/cancers1203058110.3390/cancers12030581 ↗
33. 10.1136/gut.2009.18141210.1136/gut.2009.181412 ↗
34. 10.1146/annurev‐immunol‐041015‐05531810.1146/annurev‐immunol‐041015‐055318 ↗
35. 10.1016/j.immuni.2020.04.01110.1016/j.immuni.2020.04.011 ↗
36. 10.1200/JCO.21.0261610.1200/JCO.21.02616 ↗
37. 10.1158/2159‐8290.CD‐22‐087610.1158/2159‐8290.CD‐22‐0876 ↗
38. Phase 2 Study of Vismodegib, a Hedgehog Inhibitor, Combined With Gemcitabine and Nab‐Paclitaxel in Patients With Untreated Metastatic Pancreatic Adenocarcinoma10.1038/s41416-019-0683-3 ↗
39. Depletion of Carcinoma‐Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer With Reduced Survival10.1016/j.ccr.2014.04.005 ↗
40. 10.17140/POJ‐3‐e01010.17140/POJ‐3‐e010 ↗
41. 10.1186/s12943‐022‐01670‐110.1186/s12943‐022‐01670‐1 ↗
42. 10.1016/j.ebiom.2024.10537410.1016/j.ebiom.2024.105374 ↗
43. 10.1158/2159‐8290.CD‐23‐058410.1158/2159‐8290.CD‐23‐0584 ↗
44. 10.1158/1078‐0432.CCR‐22‐226310.1158/1078‐0432.CCR‐22‐2263 ↗
45. 10.1038/s41525‐022‐00333‐w10.1038/s41525‐022‐00333‐w ↗
46. 10.1208/s12248‐020‐00466‐910.1208/s12248‐020‐00466‐9 ↗
47. 10.1016/j.ccell.2022.01.00110.1016/j.ccell.2022.01.001 ↗
48. A Scalable SCENIC Workflow for Single‐Cell Gene Regulatory Network Analysis10.1038/s41596-020-0336-2 ↗
49. 10.1088/0031‐9155/44/6/10110.1088/0031‐9155/44/6/101 ↗